Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 14 studies | 28% ± 12% | |
| mesothelial cell | 8 studies | 42% ± 9% | |
| endothelial cell | 6 studies | 21% ± 4% | |
| endothelial cell of artery | 6 studies | 31% ± 6% | |
| adventitial cell | 5 studies | 47% ± 3% | |
| vein endothelial cell | 3 studies | 32% ± 16% | |
| endocardial cell | 3 studies | 33% ± 8% | |
| smooth muscle cell | 3 studies | 34% ± 6% |
Insufficient scRNA-seq data for expression of PTGIS at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 10199.69 | 180 / 180 | 80% | 24.86 | 342 / 430 |
| breast | 90% | 6919.35 | 415 / 459 | 84% | 16.69 | 937 / 1118 |
| prostate | 82% | 5497.90 | 201 / 245 | 91% | 20.36 | 457 / 502 |
| lung | 87% | 4981.68 | 503 / 578 | 80% | 18.08 | 929 / 1155 |
| bladder | 95% | 22412.81 | 20 / 21 | 51% | 14.80 | 256 / 504 |
| uterus | 99% | 23091.69 | 168 / 170 | 33% | 21.29 | 153 / 459 |
| esophagus | 78% | 8093.09 | 1121 / 1445 | 45% | 10.72 | 82 / 183 |
| intestine | 73% | 6554.09 | 704 / 966 | 41% | 11.96 | 217 / 527 |
| skin | 37% | 1387.26 | 666 / 1809 | 69% | 18.08 | 327 / 472 |
| blood vessel | 100% | 25979.85 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 13.49 | 1 / 1 |
| stomach | 43% | 4308.62 | 153 / 359 | 56% | 17.25 | 160 / 286 |
| adipose | 95% | 10248.00 | 1139 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 2% | 38.31 | 6 / 328 | 90% | 45.11 | 161 / 178 |
| heart | 79% | 5309.48 | 684 / 861 | 0% | 0 | 0 / 0 |
| thymus | 48% | 1911.91 | 315 / 653 | 23% | 2.18 | 139 / 605 |
| kidney | 15% | 475.64 | 13 / 89 | 45% | 8.62 | 404 / 901 |
| liver | 13% | 371.21 | 29 / 226 | 25% | 3.28 | 100 / 406 |
| adrenal gland | 11% | 264.47 | 28 / 258 | 26% | 2.59 | 59 / 230 |
| brain | 0% | 6.48 | 5 / 2642 | 29% | 2.81 | 206 / 705 |
| tonsil | 0% | 0 | 0 / 0 | 16% | 1.31 | 7 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 14% | 2.75 | 4 / 29 |
| eye | 0% | 0 | 0 / 0 | 13% | 0.78 | 10 / 80 |
| muscle | 5% | 118.88 | 37 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 1% | 26.00 | 7 / 929 | 0% | 0 | 0 / 0 |
| spleen | 0% | 7.34 | 1 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0097190 | Biological process | apoptotic signaling pathway |
| GO_0019371 | Biological process | cyclooxygenase pathway |
| GO_0034356 | Biological process | NAD biosynthesis via nicotinamide riboside salvage pathway |
| GO_0045766 | Biological process | positive regulation of angiogenesis |
| GO_0071354 | Biological process | cellular response to interleukin-6 |
| GO_0006690 | Biological process | icosanoid metabolic process |
| GO_0035360 | Biological process | positive regulation of peroxisome proliferator activated receptor signaling pathway |
| GO_0071456 | Biological process | cellular response to hypoxia |
| GO_0045019 | Biological process | negative regulation of nitric oxide biosynthetic process |
| GO_0071347 | Biological process | cellular response to interleukin-1 |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0050728 | Biological process | negative regulation of inflammatory response |
| GO_0001516 | Biological process | prostaglandin biosynthetic process |
| GO_1900119 | Biological process | positive regulation of execution phase of apoptosis |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005901 | Cellular component | caveola |
| GO_0005634 | Cellular component | nucleus |
| GO_0004497 | Molecular function | monooxygenase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0020037 | Molecular function | heme binding |
| GO_0106256 | Molecular function | hydroperoxy icosatetraenoate dehydratase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0016705 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen |
| GO_0008116 | Molecular function | prostaglandin-I synthase activity |
| Gene name | PTGIS |
| Protein name | Prostacyclin synthase (EC 5.3.99.4) (Prostaglandin I2 synthase) Prostacyclin synthase (EC 5.3.99.4) (Hydroperoxy icosatetraenoate dehydratase) (EC 4.2.1.152) (Prostaglandin I2 synthase) Alternative protein PTGIS |
| Synonyms | CYP8 CYP8A1 |
| Description | FUNCTION: Catalyzes the biosynthesis and metabolism of eicosanoids. Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2), a potent mediator of vasodilation and inhibitor of platelet aggregation . Additionally, displays dehydratase activity, toward hydroperoxyeicosatetraenoates (HPETEs), especially toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-HPETE) . . FUNCTION: Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2). . |
| Accessions | L8EC60 Q6LEN2 ENST00000244043.5 Q16647 |
